- Home
- GILD
GILD
Gilead Sciences Inc.
as 05-30-2025 2:36pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 129.9B | IPO Year: | 1992 |
| Target Price: | $109.00 | AVG Volume (30 days): | 8.6M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.73 | EPS Growth: | 1118.07 |
| 52 Week Low/High: | $62.07 - $119.96 | Next Earning Date: | 04-24-2025 |
| Revenue: | $28,735,000,000 | Revenue Growth: | 4.68% |
| Revenue Growth (this year): | 1.54% | Revenue Growth (next year): | 3.70% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | GILD | Chief Financial Officer | May 15 '25 | Sell | $99.82 | 2,500 | $249,550.00 | 165,674 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Apr 15 '25 | Sell | $106.40 | 2,500 | $266,000.00 | 165,674 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Mar 17 '25 | Sell | $110.53 | 2,500 | $276,325.00 | 165,674 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Mar 10 '25 | Sell | $117.90 | 17,929 | $2,118,695.72 | 165,674 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Zacks
a day ago
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Zacks
4 days ago
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
Clinical Trials Arena
4 days ago
Gilead’s Phase III trial for breast cancer therapy meets primary goal
Insider Monkey
6 days ago
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump
TipRanks
6 days ago
Gilead announces ASCENT-03 study meets primary endpoint
MT Newswires
7 days ago
Gilead Sciences Insider Sold Shares Worth $3,010,564, According to a Recent SEC Filing
Simply Wall St.
7 days ago
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.